Clinigen and Deciphera Sign Distribution Agreement

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical Services and Products company, announces it has signed a distribution agreement, with Deciphera Pharmaceuticals (‘Deciphera’) for the supply and distribution of QINLOCK® (ripretinib) into multiple countries across the globe.

QINLOCK® was approved by the European Medicines Agency (EMA) in November 2021 for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. Under the agreement, Clinigen will supply QINLOCK® into multiple countries where it is not yet commercially available.

Clinigen will act as the main point of contact for healthcare professionals wanting to access QINLOCK®, managing all elements of the process including order and enquiry management, regulatory compliance, and logistics.

Sam Herbert, Chief Operating Officer, Clinigen, said:

“We are pleased to continue to partner with Deciphera to enable broader access to QINLOCK® for patients with advanced GIST. GIST is a complex disease with a high unmet need and this agreement will help to ensure healthcare professionals can obtain compliant access to a critical medicine that is not commercially available in their country.”

Healthcare professionals can obtain details about the product by calling the Clinigen customer service team at +44 (0) 1932 824100, emailing or going online at

Patients seeking medical information should contact their physician.

For further information, please contact:

Clinigen Group plc
Sam Herbert, Group Chief Operating Officer
Rob Fox, VP Investor Relations and Corporate Development
+44 (0) 1283 495010

Consilium Strategic Communications
Mary-Jane Elliott / Matthew Cole / Jessica Hodgson
Tel: +44 (0) 20 3709 5700

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical Services and Products company focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 120 countries.

For more information on Clinigen, please visit

About Deciphera

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Deciphera leverages their proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from their platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST.
For more information, visit and follow us on LinkedIn and Twitter (@Deciphera).


QINLOCK® is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases by using a dual mechanism of action that regulates the kinase switch pocket and activation loop. QINLOCK® inhibits primary and secondary KIT mutations in exons 9, 11, 13, 14, 17, and 18 involved in GIST, as well as the primary exon 17 D816V mutation. QINLOCK® also inhibits primary PDGFRA mutations in exons 12, 14, and 18, including the exon 18 D842V mutation, involved in a subset of GIST.